Immodulon to Participate in the Wells Fargo Virtual Private Biotech Symposium
UXBRIDGE, United Kingdom, April 29, 2024 (GLOBE NEWSWIRE) -- Immodulon, a late-stage clinical biotechnology company focused on developing a broad spectrum immunomodulator to improve the lives of patients suffering from difficult-to-treat cancers, today announced that Gertjan Bartlema, Chief Executive Officer, and Peter Greaney, PhD, Chief Business Officer, will participate in meetings with investors at the Wells Fargo Virtual Private Biotech Symposium on Monday, May 6, 2024. Investors are encouraged to contact their Wells Fargo representative to schedule a meeting.
About Immodulon
Immodulon is a late-stage clinical biotechnology company developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. Immodulon is developing IMM-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumours including those considered to be immunologically “cold,” such as pancreatic cancer. For more information, please visit www.immodulon.com.
Contacts:
Josh Rappaport and William Gramig
Stern Investor Relations, Inc.
josh.rappaport@sternir.com
william.gramig@sternir.com
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Arista Stock a Buy, a Sell, or Fairly Valued?
-
A Cheap Dividend Aristocrat to Buy Before It Bounces Back